33 results

  • Actemra

    (tocilizumab)
    Genentech, Inc.
    Usage: ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome from CAR T-cell therapy, and COVID-19 in hospitalized adults requiring respiratory support.

  • Activase (alteplase)

    (Alteplase)
    Genentech, Inc.
    Usage: Activase is indicated for the treatment of acute ischemic stroke, acute myocardial infarction (AMI) to reduce mortality and heart failure incidence, and lysis of acute massive pulmonary embolism with significant obstruction or unstable hemodynamics. Treatment should be initiated quickly, particularly for stroke within 3 hours of symptom onset.

  • Alecensa

    (ALECTINIB HYDROCHLORIDE)
    Genentech, Inc.
    Usage: ALECENSA is indicated for the adjuvant treatment of adult patients with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with metastatic ALK-positive NSCLC, both confirmed by an FDA-approved test.

  • Avastin

    (bevacizumab)
    Genentech, Inc.
    Usage: Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and advanced epithelial ovarian or peritoneal cancers, often in combination with other chemotherapy agents.

  • Cellcept

    (Mycophenolate Mofetil)
    Genentech, Inc.
    Usage: CELLCEPT (mycophenolate mofetil) is indicated for the prevention of organ rejection in adult and pediatric patients (3 months and older) receiving allogeneic kidney, heart, or liver transplants, used alongside other immunosuppressants.

  • Columvi

    (Glofitamab)
    Genentech, Inc.
    Usage: COLUMVI is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL, NOS) or large B-cell lymphoma from follicular lymphoma, following two or more lines of systemic therapy. This indication is granted under accelerated approval, pending further confirmation of clinical benefit.

  • Cotellic

    (COBIMETINIB)
    Genentech, Inc.
    Usage: COTELLIC® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with vemurafenib, and as a single agent for adult patients with histiocytic neoplasms.

  • Erivedge

    (vismodegib)
    Genentech, Inc.
    Usage: ERIVEDGE is indicated for adults with metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred after surgery, as well as those who are not candidates for surgery or radiation.

  • Fuzeon

    (Enfuvirtide)
    Genentech, Inc.
    Usage: FUZEON® is indicated for the treatment of HIV-1 infection in treatment-experienced patients who show evidence of ongoing HIV-1 replication despite receiving antiretroviral therapy, in combination with other antiretroviral agents.

  • Gavreto

    (Pralsetinib)
    Genentech, Inc.
    Usage: GAVRETO is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy, particularly those who are radioactive iodine-refractory.